Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)
CNY 18.81
(0.16%)
CNY 18.81
(0.16%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 137.06 Million | 250.79 Million | 123.98 Million | 121.67 Million | 372.32 Million | 76.18 Million |
| Net Income | 176.11 Million | 125.72 Million | 121.64 Million | 168.07 Million | 184.62 Million | 91.47 Million |
| Depreciation & Amortization | 21.75 Million | 21.76 Million | 19.36 Million | 1.62 Million | 4.36 Million | 914.06 Thousand |
| Deferred income taxes | 986.35 Thousand | 1.66 Million | 674.63 Thousand | -96.8 Thousand | 1.41 Million | 974.2 Thousand |
| Stock-based compensation | - | -1.66 Million | -674.63 Thousand | 10.98 Million | -1.41 Million | - |
| Change in working capital | -56.08 Million | 109 Million | -11.84 Million | -64.8 Million | 168.14 Million | -40.12 Million |
| Other non-cash items | 93.88 Million | -5.69 Million | -5.18 Million | 16.77 Million | 15.19 Million | 23.91 Million |
| Investing Cash Flow | -207.46 Million | -179.86 Million | 229.64 Million | 44.35 Million | -256.02 Million | -68.87 Million |
| Investments in PPE | -186.53 Million | -75.95 Million | -21.06 Million | -13.38 Million | -32.34 Million | -25.07 Million |
| Acquisitions | 466.4 Thousand | 63 Thousand | 9290.00 | 13.44 Million | 32.34 Million | 20.88 Million |
| Investment purchases | -21.4 Million | -103.97 Million | -480 Million | -771.91 Million | -339.08 Million | -110 Million |
| Sales/Maturities of investments | - | -63 Thousand | 730.7 Million | 829.59 Million | 115.4 Million | 45.17 Million |
| Other Investing Activities | -20.93 Million | 62.99 Thousand | -0.13 | -13.38 Million | -32.34 Million | 144.08 Thousand |
| Financing Cash Flow | -97.16 Million | -77.39 Million | 1.4 Billion | -123.36 Million | -108.83 Million | 8.54 Million |
| Debt repayment | -1.16 Million | -1.33 Million | - | -80 Million | -117 Million | -70 Million |
| Dividends payments | -96 Million | -72 Million | - | -2.28 Million | -3.91 Million | -6.45 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | -4.05 Million | -11.02 Million | - | - | - |
| Other Financing Activities | -1.16 Million | -1.33 Million | 1.4 Billion | -41.08 Million | 12.08 Million | 84.99 Million |
| Accounts receivables | 49.3 Million | 31.65 Million | -61.53 Million | 13.51 Million | 123.1 Million | -51.68 Million |
| Accounts payables | -46.28 Million | 100.89 Million | 3.91 Million | -17.73 Million | 21.37 Million | 15.16 Million |
| Inventory | -59.1 Million | -25.2 Million | 45.09 Million | -60.48 Million | 22.25 Million | -4.57 Million |
| Other working capital | -45.3 Million | 1.66 Million | 674.63 Thousand | -96.87 Thousand | 1.41 Million | -35.54 Million |
| Cash at beginning of period | 1.85 Billion | 1.85 Billion | 105.16 Million | 65.27 Million | 56.65 Million | 40.8 Million |
| Cash at end of period | 1.69 Billion | 1.85 Billion | 1.85 Billion | 105.16 Million | 65.27 Million | 56.65 Million |
| Capital Expenditure | -186.53 Million | -75.95 Million | -21.06 Million | -13.38 Million | -32.34 Million | -25.07 Million |
| Effect of forex changes on cash | 3.81 Million | 4.93 Million | -4.42 Million | -2.75 Million | 1.15 Million | -12.46 Thousand |
| Net cash flow / Change in cash | -163.76 Million | -1.52 Million | 1.75 Billion | 39.89 Million | 8.61 Million | 15.84 Million |
| Free Cash Flow | -49.46 Million | 174.84 Million | 102.91 Million | 108.28 Million | 339.98 Million | 51.1 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | 31.11 Million | 37.38 Million | 176.11 Million | 31.6 Million | 31.47 Million |
| Depreciation & Amortization | - | 5.34 Million | - | 21.75 Million | 5.36 Million | 5.36 Million |
| Deferred income taxes | - | - | - | 986.35 Thousand | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 2.02 Million | - | -56.08 Million | -9.79 Million | 37.27 Million |
| Other non-cash items | - | -8.24 Million | -21.97 Million | 93.88 Million | 27.84 Million | 4.17 Million |
| Investing Cash Flow | -518.43 Million | -520.57 Million | -47.18 Million | -207.46 Million | -88.27 Million | -35.79 Million |
| Investments in PPE | -27.32 Million | -34.57 Million | -57.22 Million | -186.53 Million | -88.36 Million | -36.13 Million |
| Acquisitions | - | 18.61 Thousand | 39.86 Thousand | 466.4 Thousand | 88.89 Thousand | 341.45 Thousand |
| Investment purchases | -502.11 Million | -552.23 Million | - | -21.4 Million | -1.4 Million | 1.4 Million |
| Sales/Maturities of investments | 11 Million | 66.21 Million | 10 Million | - | - | -1.74 Million |
| Other Investing Activities | 4180.00 | -486.09 Million | 11.11 Million | -20.93 Million | 1.4 Million | 341.45 Thousand |
| Financing Cash Flow | - | -138.24 Million | - | -97.16 Million | -1.16 Million | -2.14 Million |
| Debt repayment | - | - | - | -1.16 Million | - | - |
| Dividends payments | - | -138.24 Million | - | -96 Million | - | -2.14 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | -1.16 Million | -1.16 Million | -2.14 Million |
| Accounts receivables | - | 8.38 Million | - | 49.3 Million | 49.3 Million | 27.41 Million |
| Accounts payables | - | - | - | -46.28 Million | - | - |
| Inventory | - | -6.35 Million | - | -59.1 Million | -59.1 Million | 9.86 Million |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 1.02 Billion | 1.66 Billion | 1.69 Billion | 1.85 Billion | 1.72 Billion | 1.73 Billion |
| Cash at end of period | 520.74 Million | 1.02 Billion | 1.66 Billion | 1.69 Billion | 1.69 Billion | 1.72 Billion |
| Capital Expenditure | -27.32 Million | -34.57 Million | -57.22 Million | -186.53 Million | -88.36 Million | -36.13 Million |
| Effect of forex changes on cash | -486.63 Thousand | 846.53 Thousand | 551 Thousand | 3.81 Million | 298.28 Thousand | 1.48 Million |
| Net cash flow / Change in cash | -501.91 Million | -640.44 Million | -31.22 Million | -163.76 Million | -35.07 Million | -795.85 Thousand |
| Free Cash Flow | -27.32 Million | -17.04 Million | -41.81 Million | -49.46 Million | -34.29 Million | -480.76 Thousand |
FBU
ONPH
S32
300762
3013
ERO